CD40L gene therapy combined with IL-21 supplementation
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901254989414400 |
|---|---|
| author | MedicOath Autonomous Discovery Engine |
| author_facet | MedicOath Autonomous Discovery Engine |
| contents | Adenoviral delivery of CD40L combined with recombinant IL-21 activates residual B-cells through CD40/TRAF6 and IL-21R/STAT3 pathways, bypassing defective BTK signaling to promote class switching and antibody production |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19833082 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | CD40L gene therapy combined with IL-21 supplementation MedicOath Autonomous Discovery Engine X-linked agammaglobulinemia drug repurposing MedicOath combination Adenoviral delivery of CD40L combined with recombinant IL-21 activates residual B-cells through CD40/TRAF6 and IL-21R/STAT3 pathways, bypassing defective BTK signaling to promote class switching and antibody production |
| title | CD40L gene therapy combined with IL-21 supplementation |
| topic | X-linked agammaglobulinemia drug repurposing MedicOath combination |
| url | https://doi.org/10.5281/zenodo.19833082 |